ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2002

Pain and Physical Function, but Not Fatigue, Track with Disease Activity in Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis

Laura Cappelli1, Cyd Eaton1, Yunzhi Wang1, Michelle Jones2 and Clifton Bingham3, 1Johns Hopkins School of Medicine, Baltimore, MD, 2Johns Hopkins School of Medicine, Pittsburgh, PA, 3Johns Hopkins University, Baltimore, MD

Meeting: ACR Convergence 2024

Keywords: Fatigue, Inflammation, Patient reported outcomes

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: Immunological Complications of Medical Therapy Poster

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Immune checkpoint inhibitor-induced inflammatory arthritis (ICI-IA) is an impactful and often persistent side effect of cancer immunotherapy that can lead to permanent joint damage and negatively affect quality of life. Though there are similarities between ICI-IA and other forms of inflammatory arthritis like rheumatoid arthritis (RA), key differences exist between these conditions. Patients with ICI-IA are commonly seronegative and are clinically heterogeneous in severity of arthritis, particular joints involved, presence of tendon and myofascial inflammation, and duration of arthritis symptoms. Importantly, patients with ICI-IA also have cancer and may experience additional side effects of cancer treatment. We evaluated symptoms and impacts in patients with ICI-IA and their correlation with arthritis disease activity.

Methods: Patients at Johns Hopkins with rheumatologist diagnosed ICI-IA and who filled out PRO questionnaires at baseline rheumatology visit were included. PROs measured with PROMIS short forms in both cohorts included physical function, ability to participate in social roles, pain interference, fatigue, anxiety, depression, and sleep disturbance. Disease activity was measured by clinical disease activity index (CDAI). For demographic, clinical, and PROMIS measures, summary statistics were calculated. Patients with ICI-IA only were then divided by CDAI categories, and PROMIS scores were compared with one way ANOVA and post hoc contrasts.

Results: 100 patients with ICI-IA were included. Patients with ICI-IA were 61 years old on average and more commonly female (59.2%). Melanoma was the most common cancer followed by lung cancer (Table 1). Average CDAI was 20.23 indicating a moderate disease activity (Table 1). Patients with ICI-IA had worsened levels of pain interference, fatigue, and physical function as compared to the population norm of 50, while anxiety and depression were close to population normative values (Table 2). When PROs were compared by CDAI category for ICI-IA, several were worse in patients with high disease activity as compared to those with low or moderate disease activity (Table 3). Specifically, pain interference was higher and the ability to participate and physical function were lower (worsened) in those with high disease activity. Interestingly fatigue was similarly increased compared to population norms regardless of IA disease activity.

Conclusion: Patients with ICI-IA have worsened pain interference, physical function, ability to participate, and fatigue compared to population normative values, while anxiety and depression were similar to the general population. Some of these symptoms and impacts increase with IA disease activity, but fatigue similarly affects patients with ICI-IA regardless of CDAI. These findings highlight the severity of impacts of ICI-IA on health-related quality of life, but also show that fatigue may be troublesome for patients with ICI-IA regardless of their arthritis disease activity.

Supporting image 1

Table 1: Demographic and clinical features of included patients with ICI-IA

Supporting image 2

Table 2: Mean and median PRO scores

Supporting image 3

Table 3: Comparison of PROs by CDAI category at baseline for patients with ICI-IA


Disclosures: L. Cappelli: Amgen, 2, Bristol-Myers Squibb(BMS), 5; C. Eaton: None; Y. Wang: None; M. Jones: None; C. Bingham: AbbVie/Abbott, 2, Bristol-Myers Squibb(BMS), 5, Eli Lilly, 2, sanofi, 2.

To cite this abstract in AMA style:

Cappelli L, Eaton C, Wang Y, Jones M, Bingham C. Pain and Physical Function, but Not Fatigue, Track with Disease Activity in Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/pain-and-physical-function-but-not-fatigue-track-with-disease-activity-in-immune-checkpoint-inhibitor-induced-inflammatory-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pain-and-physical-function-but-not-fatigue-track-with-disease-activity-in-immune-checkpoint-inhibitor-induced-inflammatory-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology